BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10405132)

  • 1. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
    Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
    J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
    Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas.
    Sakamoto H; Nakai Y; Ohashi Y; Matsuda M; Sakashita T; Nasako Y; Kitayama H; Kawabe J; Okamura T; Ochi H
    Acta Otolaryngol Suppl; 1998; 538():254-60. PubMed ID: 9879431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
    Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
    Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.
    Yao M; Graham MM; Hoffman HT; Smith RB; Funk GF; Graham SM; Dornfeld KJ; Skwarchuk M; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1001-10. PubMed ID: 15234033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck.
    Kim SY; Lee SW; Nam SY; Im KC; Kim JS; Oh SJ; Ahn SD; Shin SS; Choi EK; Kim JH
    J Nucl Med; 2007 Mar; 48(3):373-8. PubMed ID: 17332614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
    Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
    J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using
    Noij DP; Jagesar VA; de Graaf P; de Jong MC; Hoekstra OS; de Bree R; Castelijns JA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):296-305.e2. PubMed ID: 28539202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CT and ¹⁸F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy.
    Inohara H; Enomoto K; Tomiyama Y; Yoshii T; Osaki Y; Higuchi I; Inoue T; Hatazawa J
    Acta Otolaryngol; 2009 Aug; 129(8):893-9. PubMed ID: 18839385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
    Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
    Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
    Kostakoglu L; Goldsmith SJ
    J Nucl Med; 2004 Jan; 45(1):56-68. PubMed ID: 14734674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of positron emission tomography in occult primary head and neck cancers.
    Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
    Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study.
    Pietsch C; de Galiza Barbosa F; Hüllner MW; Schmid DT; Haerle SK; Huber GF; Studer G; Hany TF; Veit-Haibach P
    BMC Med Imaging; 2015 Dec; 15():60. PubMed ID: 26714448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
    Minn H; Lapela M; Klemi PJ; Grénman R; Leskinen S; Lindholm P; Bergman J; Eronen E; Haaparanta M; Joensuu H
    J Nucl Med; 1997 Dec; 38(12):1907-11. PubMed ID: 9430467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.